Enliven Therapeutics Inc
ELVNHealthcare|Biotechnology|USA
$51.09
-1.09 (-2.09%)
Tangible Book
$7.45
Financials
Financial Snapshot
Market Cap
$3.65B
Enterprise Value
$452.1M
Revenue (TTM)
$0.00
Net Income (TTM)
$-98.8M
Cash & Equivalents
—
Net Cash/Share
$7.24
Free Cash Flow (TTM)
$-65.6M
Operating CF (TTM)
$-65.5M
Debt/Equity
0
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$16.4M
Monthly Burn
$5.5M
Est. Runway
—
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $130.4M | $110.0M | $75.5M | $253.1M | $313.4M | $462.6M | $452.4M | |
| Operating Cash Flow | $-8.5M | $-19.1M | $-32.1M | $-61.3M | $-73.2M | $-70.3M | $-65.5M | |
| Free Cash Flow | $-9.0M | $-19.3M | $-32.7M | $-61.4M | $-73.2M | $-70.5M | $-65.6M | |
| Capital Expenditure | $-461.0K | $-191.0K | $-612.0K | $-149.0K | $-44.0K | $-158.0K | $-138.0K | |
| Financing Cash Flow | $130.5M | $-1.0M | $-1.8M | $234.3M | $133.2M | $218.9M | $228.7M |
R&D Spending
R&D (TTM)
$81.6M
R&D Intensity
—
R&D Growth YoY
-4.9%
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $8.2M | $20.5M | $31.0M | $64.6M | $80.8M | $85.9M | $81.6M | |
| R&D % of Revenue | — | — | — | — | — | — | — | |
| SG&A | $1.1M | $4.3M | $7.8M | $19.0M | $23.8M | $33.8M | $34.1M |
Income Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $8.2M | $20.5M | $31.0M | $64.6M | $80.8M | $85.9M | $81.6M | |
| SG&A | $1.1M | $4.3M | $7.8M | $19.0M | $23.8M | $33.8M | $34.1M | |
| Operating Income | $-9.3M | $-24.8M | $-38.8M | $-83.5M | $-104.6M | $-119.7M | $-115.8M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | $-19.0M | $-24.7M | $-37.7M | $-71.6M | $-88.8M | $-103.7M | $-98.8M | |
| Net Income | $-19.0M | $-24.7M | $-37.7M | $-71.6M | $-89.0M | $-103.7M | $-98.8M | |
| EPS (Diluted) | -0.46 | -0.60 | -0.92 | -2.01 | -1.89 | -1.83 | -1.67 | |
| EBITDA | $-9.3M | $-24.6M | $-38.6M | $-83.2M | $-104.2M | $-119.4M | $-115.6M | |
| Shares Out. (M) | 41.10 | 41.10 | 41.10 | 35.55 | 47.07 | 56.66 | 62.80 |
Balance Sheet
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $130.4M | $110.0M | $75.5M | $100.1M | $124.1M | $98.9M | $132.2M | |
| Marketable Securities | $0.00 | $0.00 | $0.00 | $153.0M | $189.3M | $363.7M | $320.2M | |
| Total Current Assets | $130.6M | $110.7M | $77.8M | $266.2M | $318.1M | $474.9M | $463.1M | |
| Total Assets | $131.0M | $113.3M | $83.3M | $271.9M | $325.8M | $476.2M | $464.9M | |
| Total Current Liabilities | $1.5M | $5.8M | $9.7M | $25.9M | $15.9M | $16.6M | $11.5M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $151.3M | $156.2M | $160.1M | $26.0M | $15.9M | $16.6M | $11.5M | |
| Stockholders' Equity | $-20.3M | $-42.9M | $-76.8M | $245.9M | $309.8M | $459.6M | $453.4M | |
| Retained Earnings | $-20.5M | $-45.2M | $-82.9M | $-154.4M | $-243.5M | $-347.2M | $-370.8M |
Cash Flow Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-8.5M | $-19.1M | $-32.1M | $-61.3M | $-73.2M | $-70.3M | $-65.5M | |
| Capital Expenditure | $-461.0K | $-191.0K | $-612.0K | $-149.0K | $-44.0K | $-158.0K | $-138.0K | |
| Free Cash Flow | $-9.0M | $-19.3M | $-32.7M | $-61.4M | $-73.2M | $-70.5M | $-65.6M | |
| Investing Cash Flow | $-461.0K | $-191.0K | $-612.0K | $-148.4M | $-36.0M | $-173.8M | $-132.7M | |
| Financing Cash Flow | $130.5M | $-1.0M | $-1.8M | $234.3M | $133.2M | $218.9M | $228.7M | |
| Issuance of Stock | $140.0K | $690.0K | $0.00 | $0.00 | $128.9M | $216.2M | $-458.0K | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Issuance of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Payments of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $130.0K | $1.9M | $3.2M | $12.9M | $20.2M | $34.0M | $34.6M | |
| Net Change in Cash | $121.5M | $-20.3M | $-34.5M | $24.6M | $24.0M | $-25.3M | $30.5M |
Dilution Tracker
Shares outstanding grew 52.8% over 5 years — significant dilution
Shares Outstanding
63M
5-Year Share Growth
+52.8%
Stock Issuance (TTM)
$-458.0K
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 41.10 | 41.10 | 41.10 | 35.55 | 47.07 | 56.66 | 62.80 | |
| YoY Change % | — | 0.0% | 0.0% | -13.5% | 32.4% | 20.4% | 10.8% | |
| Stock Issuance | $140.0K | $690.0K | $0.00 | $0.00 | $128.9M | $216.2M | $-458.0K | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $130.0K | $1.9M | $3.2M | $12.9M | $20.2M | $34.0M | $34.6M |
Margins & Profitability
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| EBITDA Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| FCF Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| ROE % | 0.0% | 0.0% | 0.0% | -84.7% | -32.0% | -27.0% | -22.8% | |
| ROA % | -14.5% | -20.3% | -38.3% | -40.3% | -29.8% | -25.9% | -22.1% | |
| R&D / Revenue | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / At Loss / At Loss
Industry Med.27.51
P/S—
Historical— / — / —
Industry Med.9.49
P/B6.86
Historical— / — / 6.86
Industry Med.2.93
EV/EBITDA-27.67
Historical-27.67 / — / —
Industry Med.13.02
EV/Revenue—
Historical— / — / —
Industry Med.8.59
P/FCF—
Historical— / — / —
Industry Med.27.13
Intrinsic Value Models
Tangible Book
$7.45
Net Current Assets
$7.420
Net-Net Working Capital
$7.24
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| PE Ratio | N/A | N/A | N/A | At Loss | At Loss | At Loss | At Loss | |
| PS Ratio | - | - | - | - | - | - | 0.00 | |
| PB Ratio | 0.00 | 0.00 | 0.00 | 2.32 | 3.55 | 1.99 | 6.86 | |
| EV/EBITDA | 0.00 | 0.00 | 0.00 | -3.83 | -7.56 | -3.80 | -27.67 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
—
Distress
Piotroski F-Score
3
Weak
Beneish M-Score
—
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $0.00M | $0.01M | $0.01M |
| Net Income | $-114.78M | $-161.62M | $-221.62M |
| EPS | -1.75 | -2.37 | -3.01 |
| Book Value per Share | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow per Share | 0.00 | 0.00 | 0.00 |
| Operating CF | $0.00M | $0.00M | $0.00M |